

Table S1 Familial history of cancer in the study population

Characteristic	Value, n (%)
Familial history of cancer	
Yes	15 (65.2)
No	7 (30.4)
Not reported	1 (4.3)
If yes – Relative (n=15)	
Mother	6 (40.0)
Father	1 (6.7)
Sibling	4 (26.7)
Son	1 (6.7)
Aunt	2 (13.4)
Grandfather	1 (6.7)
If yes – Cancer (n=15)	
Colon cancer	5 (33.3)
Gastric cancer	3 (20.0)
Esophagus cancer	1 (6.7)
Gallbladder cancer	1 (6.7)
Thyroid cancer	1 (6.7)
Tonsil cancer	1 (6.7)
Brain cancer	1 (6.7)
Uterine cancer	2 (13.4)

Table S2 Diagnostic characteristics of colon cancer in study population

Characteristic	Value
Side of primary tumor, n (%)	
Left sided	5 (21.7)
Right sided	18 (78.3)
Compromised colon segment, n (%)	
Cecum	1 (4.3)
Ascending colon	10 (43.5)
Hepatic flexure	2 (8.7)
Transverse colon	5 (21.7)
Descending colon	1 (4.3)
Sigmoid colon	4 (17.4)
Rectosigmoid junction	4 (17.4)
Weight at diagnosis (kg)	
Mean	70.5
Standard deviation	11.2
Height at diagnosis (cm)	
Mean	166.3
Standard deviation	7.5
Personal medical history, n (%)	
No relevant diseases	9 (39.1)
Arterial hypertension	5 (21.7)
Type II diabetes	1 (4.3)
Dyslipidemia	1 (4.3)
Polyneuropathy	1 (4.3)
Deep vein thrombosis	1 (4.3)
Myocardial infarction	1 (4.3)
Renal insufficiency	1 (4.3)
Thyroid cancer	1 (4.3)
Prostatic cancer	2 (8.7)
Tobacco consumption, n (%)	
No	14 (60.9)
Yes	9 (39.1)
Chronic alcohol consumption, n (%)	
No	23 (100)
Illegal drug consumption, n (%)	
No	23 (100)

Table S3 Symptoms at diagnosis of the study population

Characteristic	Value, n (%)
Asymptomatic finding	
No	20 (87)
Yes	3 (13)
If yes – Abdominal pain (n=20)	
No	7 (35)
Yes	13 (65)
If yes – Sudden weight loss (n=20)	
No	11 (55)
Yes	9 (45)
If yes – Rectal bleeding (n=20)	
No	14 (70)
Yes	6 (30)
If yes – Jaundice (n=20)	
No	19 (95)
Yes	1 (5)
If yes – Anemia (n=20)	
No	17 (85)
Yes	3 (15)
If yes – Sudden changes in intestinal motility (n=20)	
No	10 (50)
Yes	10 (50)

Table S4 Mutational status of the study population

Characteristic	Value, n (%)
<i>BRAF</i> mutation	
Yes	23 (100)
<i>BRAF</i> mutation – Codon	
600	22 (95.6)
466–469	1 (4.4)
<i>KRAS</i> mutation	
No	21 (91.3)
Yes	2 (8.7)
<i>NRAS</i> mutation	
No	22 (95.6)
Yes	1 (4.4)

Table S5 Cancer staging of the study population

Characteristic	Value, n (%)
AJCC staging	
II	1 (4.3)
III	5 (21.7)
IV	16 (69.6)
Not reported	1 (4.3)
ECOG performance status	
0	11 (47.8)
1	7 (30.4)
2	2 (8.7)
Histologic grade of differentiation	
Well-differentiated	3 (13.0)
Moderately differentiated	4 (17.4)
Poorly differentiated	9 (39.1)
Not reported	4 (17.4)

Table S6 Systemic treatments in the study population

Characteristic	Value, n (%)
Adjuvant treatment (stage III, n=5)	
FOLFOX	4 (80)
CAPOX	1 (20)
Palliative treatment – First line (stage IV, n=16)	
FOLFOX	7 (43.8)
FOLFOX + Bevacizumab	3 (18.8)
FOLFIRI + Bevacizumab	1 (6.3)
FOLFIRINOX	2 (12.5)
CAPOX	1 (6.3)
Not reported	2 (12.5)
Palliative treatment – Second line (n=9)	
Capecitabine	3 (33.3)
Capecitabine + Bevacizumab	2 (22.2)
FOLFIRI + Cetuximab	1 (11.1)
Cetuximab + Encorafenib	1 (11.1)
Nivolumab	1 (11.1)
Stereotactic body radiation therapy only	1 (11.1)